hepatic encephalopathy/cannabis

Lyen an sove nan clipboard la

AtikEsè klinikPatant

Chwazi kalite sòt

7 rezilta yo

Cannabinoid receptors as therapeutic targets in the management of liver diseases.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Despite recent advances in the understanding of mechanisms underlying the pathogenesis of liver diseases, therapeutic agents are still needed in several instances such as nonalcoholic fatty liver disease, alcoholic liver disease or fibrogenesis associated with chronic liver injury. Over the past

Problematic Cannabis Use and Risk of Complications in Patients with Chronic Hepatitis C.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Objectives To evaluate the risk of complication in hospitalized chronic hepatitis C (CHC), patients with cannabis use disorder (CUD). Methods We conducted a retrospective study using the nationwide inpatient sample (NIS), and included 31,623 patients (age 15-54) with a primary international

Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hepatic encephalopathy (HE) is a neuropsychiatric disorder of complex pathogenesis caused by acute or chronic liver failure. We studied the etiology of cerebral dysfunction in a murine model of HE induced by either bile duct ligation or thioacetamide administration. We report that stimulation of

Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE We have shown the beneficial effects of cannabinoids in a murine model of hepatic encephalopathy following thioacetamide and now report their effects on the liver injury. METHODS Fulminant hepatic failure (FHF) was induced by administration of 200 mg/kg thioacetamide to wild-type (WT) and

Role of cannabinoids in chronic liver diseases.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Cannabinoids are a group of compounds acting primarily via CB1 and CB2 receptors. The expression of cannabinoid receptors in normal liver is low or absent. However, many reports have proven up-regulation of the expression of CB1 and CB2 receptors in hepatic myofibroblasts and vascular endothelial

The Role of Cannabinoids in the Setting of Cirrhosis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Although the mortality rates of cirrhosis are underestimated, its socioeconomic burden has demonstrated a significant global impact. Cirrhosis is defined by the disruption of normal liver architecture after years of chronic insult by different etiologies. Treatment modalities are recommended

Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Angiogenesis in liver cirrhosis leads to splanchnic hyperemia, increased portal inflow, and portosystemic collaterals formation, which may induce lethal complications, such as gastroesophageal variceal hemorrhage and hepatic encephalopathy. Cannabinoids (CBs) inhibit angiogenesis, but the relevant

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye